| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim |
| Not yet recruiting | 4 | 240 | NA | SKYRIZI | Istituto Clinico Humanitas, AbbVie S.r.l. | Psoriasis | 01/22 | 01/22 | | |
NCT04908475 / 2020-005512-21: Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy |
|
|
| Completed | 4 | 352 | Europe, Canada, US, RoW | Risankizumab, ABBV-066, Skyrizi, Apremilast, Otezla | AbbVie | Psoriasis | 04/23 | 04/23 | | |
| Active, not recruiting | 4 | 244 | Europe | Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx | Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent | Psoriasis, Psoriasis Vulgaris | 12/25 | 12/25 | | |
| Recruiting | 4 | 100 | Europe | Venapuncture, Patient questionnaires | University Hospital, Ghent | Psoriasis Vulgaris | 12/24 | 12/24 | | |
NCT06346288: A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease |
|
|
| Recruiting | 4 | 10 | US, RoW | Breast Milk Sampling, Risankizumab, SKYRIZI | AbbVie | Inflammatory Bowel Disease | 10/25 | 02/26 | | |
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
|
|
| Active, not recruiting | 4 | 393 | Europe, Canada, US, RoW | Risankizumab, Deucravacitinib | AbbVie | Moderate Plaque Psoriasis | 03/26 | 03/26 | | |
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis |
|
|
| Completed | 4 | 214 | US | Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab | AbbVie | Genital Psoriasis, Scalp Psoriasis | 01/25 | 11/25 | | |
NCT05270733: Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics |
|
|
| Recruiting | 4 | 56 | US | Ustekinumab, Guselkumab, Risankizumab | University Hospitals Cleveland Medical Center, LEO Foundation, Case Western Reserve University | Psoriasis | 12/26 | 12/26 | | |
2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis |
|
|
| Completed | 4 | 244 | Europe | secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya | Radboudumc, ZonMw, KCE | psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Active, not recruiting | 4 | 20 | US | Risankizumab-Rzaa, SKYRIZI, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit | Jaehwan Kim, AbbVie, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Psoriasis | 02/26 | 07/27 | | |
NCT05928039: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease |
|
|
| Recruiting | 4 | 297 | Canada | TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab, Anti-IL12/23 or anti-IL23 - Risankizumab, Anti-integrin - Vedolizumab IV, Anti-integrin - Vedolizumab IV and SC | University of Calgary, Alimentiv Inc. | Crohn Disease | 07/27 | 12/28 | | |
SOPRANO-CD, NCT05169593: Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy |
|
|
| Recruiting | 4 | 292 | Europe | Biological Drug, Risankizumab, Vedolizumab, Ustekinumab, Infliximab, Adalimumab | Universitaire Ziekenhuizen KU Leuven | Crohn Disease | 10/27 | 10/30 | | |
2019-000904-14: A study to assess the efficacy and safety in patients who have been treated for at least 6 months with secukinumab or ixekizumab and have experienced a suboptimal response and then switched to risankizumab. |
|
|
| Not yet recruiting | 3/4 | 250 | Europe | Risankizumab, ABBV-066, Solution for injection in pre-filled syringe | AbbVie, AbbVie Deutschland GmbH & Co.KG, ABBVIE DEUTSCHLAND GMBH & CO. KG, AbbVie Inc | Plaque Psoriasis / Psoriasis Vulgaris, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
